Sign up for our monthly newsletter!

Get the latest information and inspirational stories for caregivers, delivered directly to your inbox.

go back

Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch

Fierce Biotech

description

SAGE-718 is being studied in a phase 2 trial called Luminary in patients with mild cognitive impairment and mild dementia due to Alzheimer’s. The study, which is part of Sage’s CogNEXt program evaluating the drug to treat cognitive deficits in multiple indications, was geared towards determining safety.

See full story at Fierce Biotech

More Stories From

SCIENCE

description

Higher Brain Vitamin D Concentrations Tied To Better Cognitive Function, New Study Says

mindbodygreen

description

Scientists discover compound that restores lost memories in Alzheimer’s model

PsyPost

description

Elderly who feel low may be at risk of mild cognitive impairment: Study

The Statesman

MORE SCIENCE
MCI and Beyond
AboutBlogContactFAQ
YouTubeTwitterFacebookInstagramLinkedIn

© 2025 MCI and Beyond. All rights reserved.